Transgene SA (OTCMKTS:TRGNF) Short Interest Down 99.7% in July

Transgene SA (OTCMKTS:TRGNF) was the recipient of a large drop in short interest in July. As of July 31st, there was short interest totaling 5 shares, a drop of 99.7% from the July 15th total of 1,507 shares. Based on an average trading volume of 0 shares, the short-interest ratio is currently ∞ days.

Transgene Stock Performance

Shares of Transgene stock opened at $0.85 on Wednesday. The stock’s 50-day moving average is $0.85 and its 200 day moving average is $0.92. Transgene has a one year low of $0.85 and a one year high of $1.08.

Transgene Company Profile

Transgene is a clinical-stage biotechnology company headquartered in Strasbourg, France, dedicated to designing and developing targeted immunotherapies for cancer and infectious diseases. Founded in 1979, the company combines expertise in virology, gene engineering and immunology to create viral-based vectors that deliver therapeutic genes or antigens directly into patient tissues. In the United States, Transgene’s American Depositary Receipts trade under the symbol TRGNF.

The company’s proprietary platforms include an oncolytic vaccine technology that harnesses genetically modified viruses to selectively infect and destroy tumor cells while stimulating systemic anti-tumor immunity.